Cargando…

A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus

Nano-particles have been combined with antibiotics in recent studies to overcome multidrug-resistant bacteria. Here, we synthesized a nano-material in which Ag nano-particles were assembled with a ZnO nano-structure to form an Ag-ZnO (AZO) nano-composite at low temperature. This material was combine...

Descripción completa

Detalles Bibliográficos
Autores principales: Naskar, Atanu, Lee, Sohee, Lee, Yunhee, Kim, Semi, Kim, Kwang-sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558003/
https://www.ncbi.nlm.nih.gov/pubmed/32887402
http://dx.doi.org/10.3390/pharmaceutics12090841
_version_ 1783594542345224192
author Naskar, Atanu
Lee, Sohee
Lee, Yunhee
Kim, Semi
Kim, Kwang-sun
author_facet Naskar, Atanu
Lee, Sohee
Lee, Yunhee
Kim, Semi
Kim, Kwang-sun
author_sort Naskar, Atanu
collection PubMed
description Nano-particles have been combined with antibiotics in recent studies to overcome multidrug-resistant bacteria. Here, we synthesized a nano-material in which Ag nano-particles were assembled with a ZnO nano-structure to form an Ag-ZnO (AZO) nano-composite at low temperature. This material was combined with erythromycin (Ery), an antibiotic effective towards gram-positive bacteria, using three different approaches (AZO + Ery (AZE) [centrifuged (AZE1), used separately after 1-h gap (AZE2), without centrifugation (AZE3)]) to prepare a nano-antibiotic against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). X-ray diffraction analysis and transmission electron microscopy confirmed the presence of Ag nano-particles and ZnO nano-structure. The elemental and chemical state of the elements present in the AZO nano-composite were assessed by X-ray photoelectron spectroscopy. The antibacterial activity of AZE samples against both Escherichia coli and S. aureus strains including MRSA was evaluated in antibacterial and morphological analyses. The AZE3 sample showed greater antibacterial activity than the other samples and was comparable to erythromycin. AZE3 was ~20-fold less prone to developing bacterial resistance following multiple exposures to bacteria compared to erythromycin alone. The AZE3 nano-composite showed good biocompatibility with 293 human embryonic kidney cells. Our newly synthesized nano-platform antibiotics may be useful against multidrug-resistant gram-positive bacteria.
format Online
Article
Text
id pubmed-7558003
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75580032020-10-22 A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus Naskar, Atanu Lee, Sohee Lee, Yunhee Kim, Semi Kim, Kwang-sun Pharmaceutics Article Nano-particles have been combined with antibiotics in recent studies to overcome multidrug-resistant bacteria. Here, we synthesized a nano-material in which Ag nano-particles were assembled with a ZnO nano-structure to form an Ag-ZnO (AZO) nano-composite at low temperature. This material was combined with erythromycin (Ery), an antibiotic effective towards gram-positive bacteria, using three different approaches (AZO + Ery (AZE) [centrifuged (AZE1), used separately after 1-h gap (AZE2), without centrifugation (AZE3)]) to prepare a nano-antibiotic against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). X-ray diffraction analysis and transmission electron microscopy confirmed the presence of Ag nano-particles and ZnO nano-structure. The elemental and chemical state of the elements present in the AZO nano-composite were assessed by X-ray photoelectron spectroscopy. The antibacterial activity of AZE samples against both Escherichia coli and S. aureus strains including MRSA was evaluated in antibacterial and morphological analyses. The AZE3 sample showed greater antibacterial activity than the other samples and was comparable to erythromycin. AZE3 was ~20-fold less prone to developing bacterial resistance following multiple exposures to bacteria compared to erythromycin alone. The AZE3 nano-composite showed good biocompatibility with 293 human embryonic kidney cells. Our newly synthesized nano-platform antibiotics may be useful against multidrug-resistant gram-positive bacteria. MDPI 2020-09-02 /pmc/articles/PMC7558003/ /pubmed/32887402 http://dx.doi.org/10.3390/pharmaceutics12090841 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Naskar, Atanu
Lee, Sohee
Lee, Yunhee
Kim, Semi
Kim, Kwang-sun
A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus
title A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus
title_full A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus
title_fullStr A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus
title_full_unstemmed A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus
title_short A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus
title_sort new nano-platform of erythromycin combined with ag nano-particle zno nano-structure against methicillin-resistant staphylococcus aureus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558003/
https://www.ncbi.nlm.nih.gov/pubmed/32887402
http://dx.doi.org/10.3390/pharmaceutics12090841
work_keys_str_mv AT naskaratanu anewnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus
AT leesohee anewnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus
AT leeyunhee anewnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus
AT kimsemi anewnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus
AT kimkwangsun anewnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus
AT naskaratanu newnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus
AT leesohee newnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus
AT leeyunhee newnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus
AT kimsemi newnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus
AT kimkwangsun newnanoplatformoferythromycincombinedwithagnanoparticleznonanostructureagainstmethicillinresistantstaphylococcusaureus